leronlimab
Sign in to saveAlso known as PA14, PRO-140, PRO 140
Leronlimab (codenamed PRO 140) is a humanized monoclonal antibody targeted against the CCR5 receptor found on T lymphocytes of the human immune system. It is being investigated as a potential therapy in the treatment of triple negative breast cancer and HIV infection.
Wikidata facts
- Subclass of
- chemical compound
Show 2 more facts
- subject has role
- monoclonal antibody
- blocker of
- C-C motif chemokine receptor 5
via Wikidata · CC0
~3 min read
Encyclopedic overview
7 sectionsContents
- Development
- Mechanism of action
- Research
- COVID-19
- See also
- References
- External links
Leronlimab (codenamed PRO 140) is a humanized monoclonal antibody targeted against the CCR5 receptor found on T lymphocytes of the human immune system. It is being investigated as a potential therapy in the treatment of triple negative breast cancer and HIV infection.
The United States Food and Drug Administration has designated PRO 140 for fast-track approval.
Excerpted from Wikipedia’s “leronlimab” article, available under the CC BY-SA 4.0 licence.